Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage

Biochimica et Biophysica Acta - General Subjects

Volumn 1673, Issue 3, 2004, Pages 115-121

  Sumita, Chinuyo ^a   Maeda, Makiko ^a   Fujio, Yasushi ^a   Kim, Jooyeon ^a   Fujitsu, Junko ^a   Kasayama, Soji ^a   Yamamoto, Isamu ^a   Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Cytoskeletal reorganization; Macrophage; PAF AH; PPAR

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ACTIN; LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN F2 ALPHA; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR AFFECTING AGENT;

ARTICLE; ATHEROSCLEROSIS; CELL MOTILITY; CONTROLLED STUDY; CYTOSKELETON; HUMAN; HUMAN CELL; HYDROLYSIS; INFLAMMATION; MACROPHAGE; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CELL LINE; CYTOSKELETON; DINOPROST; ENZYME INDUCTION; HUMANS; MACROPHAGES; PLATELET ACTIVATING FACTOR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 3242811930     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2004.04.002     Document Type: Article

References (30)

1. Prescott S.M., Zimmerman G.A., McIntyre T.M. Platelet-activating factor. J. Biol. Chem. 265:1990;17381-17384
2. Imaizumi T., Stafforini D.M., Yamada Y., Mcintyre T.M., Prescott S.M., Zimmerman G.A. Platelet-activating factor: a mediator for clinicians. J. Intern. Med. 238:1995;5-20
3. Stafforini D.M., Elstad M.R., McIntyre T.M., Zimmerman G.A., Prescott S.M. Human macrophages secret platelet-activating factor acetylhydrolase. J. Biol. Chem. 265:1990;9682-9687
4. Stremler K.E., Stafforini D.M., Prescott S.M., McIntyre T.M. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 266:1991;11095-11103
5. Tjoelker L.W., Wilder C., Eberhardt C., Stafforini D.M., Dietsch G., Schimpf B., Hooper S., Le Trong H., Cousens L.S., Zimmerman G.A., Yamada Y., McIntyre T.M., Prescott S.M., Gray P.W. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 374:1995;549-553
6. Quarck R., De Geest B., Stengel D., Merten S.A., Lox M., Theilmeier G., Michiels C., Raes M., Bult H., Collen D., Van Veldhoven P., Ninio E., Holvoet P. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 103:2001;2495-2500
7. Stafforini D.M., Satoh K., Atkinso D.L., Tjoelker L.W., Eberhardt C., Yoshida H., Imaizumi T., Takamatsu S., Zimmerman G.A., Mclntyre T.M., Gray P.W., Prescott S.M. Platelet-activating factor acetylhydrolase deficiency. J. Clin. Invest. 97:1996;2784-2791
8. Hiramoto M., Yoshida H., Imaizumi T., Yoshimizu N., Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke. 28:1997;2417-2420
9. Yamada Y., Ichihara S., Fujimura T., Yokota M. Identification of the G994→T missense mutation in exon 9 of the plasma platelet-activating factor acethylhydorolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism. 147:1998;177-181
10. Unno N., Nakamura T., Kaneko H., Uchiyama T., Yamamoto N., Sugatani J., Miwa M., Nakamura S. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J. Vasc. Surg. 32:2000;263-267
11. Yamamoto I., Fujitsu J., Nohnen S., Igarashi T., Motomura T., Inaba M., Tsubakimori S., Azuma J. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res. Clin. Pract. 59:2003;219-224
12. Spiegelman B.M. Peroxisome proliferator-activated receptor gamma: a key regulator of adipogenesis and systemic insulin sensitivity. Eur. J. Med. Res. 2:1997;457-464
13. Zhang B., Berger J., Zhou G., Elbrecht A., Biswas S., White-Carrington S., Szalkowski D., Moller D.E. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 271:1996;31771-31774
14. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U. S. A. 91:1994;7355-7359
15. Ricote M., Li A.C., Wilson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82
16. Jiang C., Ting A.T., Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokine. Nature. 391:1998;82-86
17. Kintscher U., Goetze S., Wakino S., Kim S., Nagpal S., Chandraratna R.A., Graf K., Fleck E., Hsueh W.A., Law R.E. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur. J. Pharmacol. 401:2000;259-270
18. Han Z., Truong Q.A., Park S., Breslow J.L. Two Hsp70 family members expressed in atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S. A. 100:2003;1256-1261
19. Yengi L.G., Xiang Q., Pan J., Scatina J., Kao J., Ball S.E., Fruncillo R., Ferron G., Roland Wolf C. Quantitation of cytochrome P450 mRNA levels in human skin. Anal. Biochem. 16:2003;103-110
20. Orlando C., Pinzani P., Pazzagli M. Developments in quantitative PCR. Clin. Chem. Lab. Med. 36:1998;255-269
21. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147
22. Tessner T.G., O'Flaherty J., Wyhle R.L. Stimulation of platelet-activating factor synthesis by a nonmetabolizable bioactive analog of platelet-activating factor and influence of arachidonic acid metabolites. J. Biol. Chem. 264:1989;4794-4799
23. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278:2000;704-711
24. Iwata M., Haruta T., Usui I., Takata Y., Takano A., Uno T., Kawahara J., Ueno E., Sasaoka T., Ishibashi O., Kobayashi M. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes. 50:2001;1083-1092
25. Reginato M.J., Krakow S.L., Bailey S.T., Lazar M.A. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 273:1998;1855-1858
26. Moor K., Rosen E.D., Fitzgerald M.L., Randow F., Andersson L.P., Altshuler D., Milstone D.S., Mortensen R.M., Spiegelman B.M., Freeman M.W. The role of PPARγ in macrophage differentiation and cholesterol uptake. Nat. Med. 7:2001;41-47
27. Jackson S.M., Parhami F., Xi X.P., Berliner J.A., Hsueh W.A., Law R.E., Demer L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19:1999;2094-2104
28. Pollard T.D. The cytoskeleton, cellular motility and the reductionist agenda. Nature. 422:2003;741-745
29. Small J.V., Kaverina I., Krylyshkina O., Rottner K. Cytoskeleton cross-talk during cell motility. FEBS Lett. 452:1999;96-99
30. Lee C., Sigari F., Segrado T., Horkko S., Hama S., Subbaiah P.V., Miwa M., Navab M., Witztum J.L., Reaven P.D. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler. Thromb. Vasc. Biol. 19:1999;1437-1446